Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
作者： Bijoyesh Mookerjee , Arundathy Nirmalini Pandite , Rakesh Kumar , Maurice P. DeYoung , Kevin Baker
DOI:
关键词: Chemistry 、 Mesothelioma 、 Pathology 、 Cancer research 、 Extracellular 、 Fibroblast growth factor receptor 1
摘要: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. and at least one anti-angiogenic agent
lens.org 参考文章(17)
Mika K. Derynck, Jennifer O'Hara Lauchle, Methods of treating mesothelioma with a pi3k inhibitor compound ,(2012)
Stanley R. Frankel, Chandra Belani, Carolyn Paradise, Suresh Sakkarai Ramalingam, Judy Chiao, Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies ,(2006)
Harold Keer, Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins ,(2011)
Ross E. Longley, Robert A. Holton, C10 cyclopropyl ester substituted taxane compositions ,(2006)
Suraj Amonkar, Brian C. Mansfield, Ping F. Yip, Greg P. Bertenshaw, Predictive markers for ovarian cancer ,(2008)
Diane Hollenbaugh, Justin Wong, Ernestine Lee, Kevin Hestir, Ali Sadra, Elizabeth Bosch, Ge Wu, Stephen K. Doberstein, Hongbing Zhang Zhang, Minmin Qin Qin, Lewis T. Williams, Compositions and methods of treating disease with fgfr fusion proteins ,(2006)
David I. Bellovin, Servando Palencia, Kevin Hestir, Ernestine Lee, M. Phillip DeYoung, Thomas Brennan, Gerrit Los, Kevin Baker, Abstract 5449: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC Cancer Research. ,vol. 74, pp. 5449- 5449 ,(2014) , 10.1158/1538-7445.AM2014-5449
A. Tolcher, K. Papadopolous, A. Patniak, E. Heath, A. Weise, T. Prokop, S. Morrone, J. Zanghi, H.N. Keer, P. LoRusso, 381 Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) in patients with advanced malignancies Ejc Supplements. ,vol. 8, pp. 121- ,(2010) , 10.1016/S1359-6349(10)72088-7
Tadashi Ogawa, Koichi Takayama, Nobuyuki Takakura, Seigo Kitano, Hikaru Ueno, Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Therapy. ,vol. 9, pp. 633- 640 ,(2002) , 10.1038/SJ.CGT.7700478
R. Cao, H. Ji, N. Feng, Y. Zhang, X. Yang, P. Andersson, Y. Sun, K. Tritsaris, A. J. Hansen, S. Dissing, Y. Cao, Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis Proceedings of the National Academy of Sciences of the United States of America. ,vol. 109, pp. 15894- 15899 ,(2012) , 10.1073/PNAS.1208324109